TY - JOUR
T1 - Depressive symptoms carry an increased risk for suicidal ideation and behavior in bipolar disorder without any additional contribution of mixed symptoms
AU - of the National Network of Depression Centers Bipolar Disorders Interest Group
AU - Fiedorowicz, Jess G.
AU - Persons, Jane E.
AU - Assari, Shervin
AU - Ostacher, Michael J.
AU - Zandi, Peter
AU - Wang, Po W.
AU - Thase, Michael E.
AU - Frye, Mark A.
AU - Coryell, William
N1 - Funding Information:
This work was made possible by a research collaboration supported by the National Network of Depression Centers (NNDC), an inter-dependent nonprofit consortium of 26 academic depression centers. The CCR was also supported through CTSA grant award UL1TR000422 to the Michigan Institute for Clinical Health Research. JGF is funded by the National Heart, Lung, and Blood Institute (2P01HL014388), the National Center for Advancing Translational Science (U54TR001356 and UL1TR002345), the National Institute of Mental Health (1R01MH111578) and Myriad Genetics, Inc.Jess Fiedorowicz is supported by the National Heart Lung and Blood Institute (P01HL014388), the Institute for Clinical and Translational Science at the University of Iowa (U54TR001356), and Myriad Genetics, Inc.(grant and consulting). Shervin Assari is partially supported by the Heinz C. Prechter Bipolar Research Fundand the Richard Tam Foundationat the University of Michigan Depression Center. Dr. Ostacher is a full-time employee of the Department of Veterans Affairs. He reports being advisory/consultant to Acadia, Eli Lily, Johnson & Johnson, Lundbeck, Otsuka, Sunovion, and Supernus Pharmaceuticals, and has received grant support from Palo Alto Health Sciences and the National Institute on Drug Abuse in the past three years. Dr. Thase has no disclosures pertaining to this research. He does report the following other relationships during the past three years. He was an advisory/consultant to Acadia, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Johnson & Johnson (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Merck, Mocksha8, Nestlé (PamLab), Neuronetics, Novartis, Otsuka, Pfizer, Shire, Sunovion, and Takeda. He has received grant support from the National Institute of Mental Health, the Agency for Healthcare Research and Quality, the Patient Centered Outcomes Research Institute, Acadia, Alkermes, Assurex, Avanir, Forest Pharmaceuticals, Johnson & Johnson, Otsuka Pharmaceuticals, and Takeda. Dr. Thase received royalties from the American Psychiatric Press, Guilford Publications, Herald House and W.W. Norton & Company, Inc. Dr. Thase's spouse, Dr. Diane Sloan, works for Peloton Advantage, which does business with Pfizer and AstraZeneca. Dr. Mark Frye also has no disclosures pertaining to this research. He has received grant support from AssureRx, Mayo Foundation, Myriad, National Institute of Alcohol Abuse and Alcoholism, National Institute of Mental Health, and Pfizer. He has served as a consultant (Mayo) to Janssen, Mitsubishi Tanabe Pharma Corporation, Myriad, Neuralstem, Inc., Otsuka American Pharmaceutical, Sunovion, and Teva Pharmaceuticals. All other authors have no potential conflicts of interest to disclose.This work was made possible by a research collaboration supported by the National Network of Depression Centers (NNDC), an inter-dependent nonprofit consortium of 26 academic depression centers. The CCR was also supported through CTSA grant award UL1TR000422 to the Michigan Institute for Clinical Health Research. Thanks to NNDC Executive Director Pat Rinvelt, MBA for her assistance with data sharing, coordination, and editing. Thanks to Caleb Adler and Wendy Marsh for feedback on the statistical analysis plan.
Funding Information:
This work was made possible by a research collaboration supported by the National Network of Depression Centers (NNDC), an inter-dependent nonprofit consortium of 26 academic depression centers. The CCR was also supported through CTSA grant award UL1TR000422 to the Michigan Institute for Clinical Health Research . JGF is funded by the National Heart, Lung, and Blood Institute ( 2P01HL014388 ), the National Center for Advancing Translational Science ( U54TR001356 and UL1TR002345 ), the National Institute of Mental Health ( 1R01MH111578 ) and Myriad Genetics, Inc .
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Objectives: To determine whether the risk of suicidal ideation or behavior during mixed states exceeds that attributable to the depressive components of these states alone in bipolar disorder. Methods: We utilized real-world, longitudinal clinical data collected on 290 patients with bipolar disorders (bipolar I, bipolar II, and bipolar not otherwise specified (NOS)) from the National Network of Depression Centers (NNDC) Clinical Care Registry (CCR) seen for 891 visits over a mean of 27.5 weeks. Depressive symptoms were measured with the Patient Health Questionnaire-9 (PHQ-9), manic symptoms with the Altman Self-Rating Mania (ASRM), and suicidal ideation and behavior with the Columbia-Suicide Severity Rating Scale (C-SSRS), obtained as part of the routine, measurement-based care provided across the NNDC. The relations between depressive symptoms, manic symptoms, and the interaction thereof (mixed symptoms) on coinciding suicidal ideation and behavior were modeled in generalized linear mixed models. Results: Depressive symptoms, as measured by the PHQ-9, were strongly associated with suicidal ideation and behavior (p < 0.0001), while there was no significant association with manic symptoms as measured by the ASRM or the interaction between depressive and manic symptoms. Similar results were observed when the outcome was restricted to suicidal behavior and when mood was modeled categorically. There was evidence of a gender by ASRM interaction (p = 0.011) and risk of suicidal ideation or behavior was significant for women, but not men with manic symptoms. Limitations: Diagnoses were based on clinician assessment and not structured interview. Mood assessments were self-reported rather than clinician-administered. Suicidal ideation was more frequently observed than suicidal behavior (23/272 visits where outcome positive). Conclusions: Depression represents the primary mood state accounting for suicide risk in bipolar disorder. Co-occurring symptoms of mania (mixed symptoms) do not appear to convey an elevated risk for suicidal ideation or behavior beyond that explained by the depressive symptoms alone.
AB - Objectives: To determine whether the risk of suicidal ideation or behavior during mixed states exceeds that attributable to the depressive components of these states alone in bipolar disorder. Methods: We utilized real-world, longitudinal clinical data collected on 290 patients with bipolar disorders (bipolar I, bipolar II, and bipolar not otherwise specified (NOS)) from the National Network of Depression Centers (NNDC) Clinical Care Registry (CCR) seen for 891 visits over a mean of 27.5 weeks. Depressive symptoms were measured with the Patient Health Questionnaire-9 (PHQ-9), manic symptoms with the Altman Self-Rating Mania (ASRM), and suicidal ideation and behavior with the Columbia-Suicide Severity Rating Scale (C-SSRS), obtained as part of the routine, measurement-based care provided across the NNDC. The relations between depressive symptoms, manic symptoms, and the interaction thereof (mixed symptoms) on coinciding suicidal ideation and behavior were modeled in generalized linear mixed models. Results: Depressive symptoms, as measured by the PHQ-9, were strongly associated with suicidal ideation and behavior (p < 0.0001), while there was no significant association with manic symptoms as measured by the ASRM or the interaction between depressive and manic symptoms. Similar results were observed when the outcome was restricted to suicidal behavior and when mood was modeled categorically. There was evidence of a gender by ASRM interaction (p = 0.011) and risk of suicidal ideation or behavior was significant for women, but not men with manic symptoms. Limitations: Diagnoses were based on clinician assessment and not structured interview. Mood assessments were self-reported rather than clinician-administered. Suicidal ideation was more frequently observed than suicidal behavior (23/272 visits where outcome positive). Conclusions: Depression represents the primary mood state accounting for suicide risk in bipolar disorder. Co-occurring symptoms of mania (mixed symptoms) do not appear to convey an elevated risk for suicidal ideation or behavior beyond that explained by the depressive symptoms alone.
KW - Attempted suicide
KW - Bipolar disorder
KW - Depression
KW - Mania
KW - Suicidal ideation
UR - http://www.scopus.com/inward/record.url?scp=85059532007&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059532007&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2018.12.057
DO - 10.1016/j.jad.2018.12.057
M3 - Article
C2 - 30623823
AN - SCOPUS:85059532007
SN - 0165-0327
VL - 246
SP - 775
EP - 782
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -